This week let's look at the macro financials and trends (as most public orthos have posted Q3 earnings) and some other key news in 10 categories.
Smith+Nephew’s full-year guidance cut and confirmation that merger discussions with DePuy Synthes have ended anchor a week dominated by third-quarter earnings across the orthopedics sector. Rather than signaling a universal industry downturn, the latest batch of financial updates reveals a fragmented landscape: execution gaps and portfolio focus are creating stark contrasts between market leaders. Outside of big recon, capital and product momentum continue to shift toward outpatient solutions, shoulder technologies, and specialized surgical platforms.
Let’s get into it all 10.
1/ Smith+Nephew: Guidance Cut and DePuy Talks End Smith+Nephew released its Q3 trading update on Nov 4. Key Figures:
Q3 revenue reached $1.551B, up 3.4%.
US knees dropped 7.3%; US hips fell 1.0%.
Full-year underlying revenue growth guidance lowered from ~4% to ~3%.
Combination discussions with J&J DePuy officially ended, though J&J’s strategic review of Orthopaedics continues. The Takeaway: S&N’s US hip and knee drag confirms distinct execution headwi...
